Maybe some investors are cautious following previous results, but that was years ago and the company have learned and adapted accordingly. Risk vs reward here is ridiculous as those prices haven't factored in clinically significant data, only assessed based on phase 3 trials. If the results are clinically significant, hold on to your hats
dyor and gltah
Ann: Quarterly Appendix 4C and Activities Report, page-31
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
48.5¢ |
Change
0.020(4.30%) |
Mkt cap ! $266.8M | |||
| Open | High | Low | Value | Volume |
| 47.0¢ | 49.0¢ | 47.0¢ | $597.1K | 1.240M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 116859 | 48.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 48.5¢ | 77280 | 6 |
View Market Depth
| Last trade - 11.06am 29/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |